AR039689A1 - Difenilazetidinonas sustituidas, medicamentos que comprenden estos compuestos y su uso - Google Patents
Difenilazetidinonas sustituidas, medicamentos que comprenden estos compuestos y su usoInfo
- Publication number
- AR039689A1 AR039689A1 ARP030102142A ARP030102142A AR039689A1 AR 039689 A1 AR039689 A1 AR 039689A1 AR P030102142 A ARP030102142 A AR P030102142A AR P030102142 A ARP030102142 A AR P030102142A AR 039689 A1 AR039689 A1 AR 039689A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- cooh
- replaced
- radicals
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 35
- 229910052731 fluorine Inorganic materials 0.000 abstract 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- -1 COO-(C1-6) alkyl Chemical group 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- 229910006069 SO3H Inorganic materials 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 125000002015 acyclic group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 102000015636 Oligopeptides Human genes 0.000 abstract 1
- 108010038807 Oligopeptides Proteins 0.000 abstract 1
- 229910018828 PO3H2 Inorganic materials 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000002016 disaccharides Chemical group 0.000 abstract 1
- 150000002337 glycosamines Chemical class 0.000 abstract 1
- 230000000055 hyoplipidemic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
- 150000004044 tetrasaccharides Chemical group 0.000 abstract 1
- 150000004043 trisaccharides Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los compuestos son convenientes para usar como hipolipidémicos. Reivindicación 1: Un compuesto de la fórmula (1), en la que: R1, R2, R3, R4, R5, R6 independientemente uno de otro son alquileno (C1-30)-(LAG)n, donde n = 1-5 y donde uno o más átomos de carbono del radical alquileno están reemplazados por radicales arilo o heteroarilo sustituidos hasta tres veces con R7, o por radicales heterocicloalquilo o cicloalquilo (C3-10) sustituidos hasta 4 veces con R7 y uno o más átomos de carbono del radical alquileno pueden estar reemplazados por -S(O)n-, donde n = 0-2, -O-, -C(=O)-, -(C=S)-, -CH=CH-, -CsC-, -N-(alquilo (C1-6))-, -N(fenilo), -N(alquilo (C1-6)fenilo)-, -N(CO-(CH2)1-10-COOH)- o -NH-; H, F, Cl, Br, I, CF3, NO2, N3, CN, COOH, COO-alquilo (C1-6), CONH2, CONH-alquilo (C1-6), CON[alquilo (C1-6)]2, alquilo (C1-6), alquenilo (C2-6), alquinilo (C2-6), O-alquilo (C1-6), donde uno, más o todos los hidrógenos en los radicales alquilo pueden estar reemplazados por flúor; SO2-NH2, SO2NH-alquilo (C1-6), SO2N[alquilo (C1-6)]2, S-alquilo (C1-6), S-(CH2)n-fenilo, SO-alquilo (C1-6), SO-(CH2)n-fenilo, -SO2-alquilo (C1-6), SO2-(CH2)n-fenilo, donde n = 0-6 y el radical fenilo puede estar sustituido hasta dos veces con F, Cl, Br, OH, CF3, NO2, CN, OCF3, O-alquilo (C1-6), alquilo (C1-6), NH2; NH2, NH-alquilo (C1-6), N(alquilo (C1-6))2, NH-acilo (C1-7), fenilo, O-(CH2)n-fenilo, donde n = 0-6, donde el anillo fenilo puede estar mono o trisustituido con F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-alquilo (C1-6), alquilo (C1-6), NH2, NH-alquilo (C1-6), N(alquilo (C1-6))2, SO2-CH3, COOH, COO-alquilo (C1-6), CONH2; R7 es F, Cl, Br, I, CF3, NO2, N3, CN, COOH, COO-alquilo (C1-6), CONH2, CONH-alquilo (C1-6), CON[alquilo (C1-6)]2, alquilo (C1-6), alquenilo (C2-6), alquinilo (C2-6), O-alquilo (C1-6), donde uno, más o todos los hidrógenos en los radicales alquilo pueden estar reemplazados por flúor; PO3H2, SO3H, SO2-NH2, SO2NH-alquilo (C1-6), SO2N[alquilo (C1-6)]2, S-alquilo (C1-6), S-(CH2)n-fenilo, SO-alquilo (C1-6), SO2-(CH2)n-fenilo, -SO2-alquilo (C1-6), SO2-(CH2)n-fenilo, donde n = 0-6 y el radical fenilo puede estar sustituido hasta dos veces con F, Cl, Br, OH, CF3, NO2, CN, OCF3, O-alquilo (C1-6), alquilo (C1-6), NH2; C(NH)(NH2), NH2, NH-alquilo (C1-6), N(alquilo (C1-6))2, NH-acilo (C1-7), fenilo, O-(CH2)n-fenilo, donde n = 0-6, donde el anillo fenilo puede estar mono a trisustituido con F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-alquilo (C1-6), alquilo (C1-6), NH2, NH-alquilo (C1-6), N(alquilo (C1-6))2, SO2-CH3, COOH; COO-alquilo (C1-6)-, CONH2; (LAG)n es un residuo de azúcar, residuo de disacárido, residuo de trisacárido, residuo de tetrasacárido; un ácido de azúcar, un aminoazúcar; un residuo de aminoácido, un residuo de oligopéptido que comprende 2 a 9 aminoácidos; un radical de trialquilamonio acíclico, mono-, di- o tricíclico, un radical de trialquilamonioalquilo acíclico, mono, di o tricíclico, -O-(SO2)-OH; -(CH2)0-10-SO3H, -(CH2)0-10-P(O)(OH)2 -(CH2)0-10-O-P(O)(OH)2, -(CH2)0-10-COOH; -(CH2)0-10-C(=NH)(NH2); -(CH2)0-10-C(=NH)(NHOH); -NR8-C(=NR9)(NR10R11); donde n = 1-5 y R8, R9, R10 y R11 independientemente uno de otro pueden ser H, alquilo (C1-6), fenilo, alquilo (C1-6)fenilo, cicloalquilo (C3-8), y donde en cada caso al menos uno de los radicales R1 a R6 deben tener el significado alquileno (C1-30)-(LAG)n, donde n = 1-5 y uno o más átomos de carbono del radical alquileno están reemplazados por radicales arilo o heteroarilo sustituidos hasta tres veces o por radicales heterocicloalquilo o cicloalquilo (C3-10) hasta tetrasustituidos y pueden adicionalmente estar reemplazados por -S(O)n-, donde n = 0-2, -O-, -(C=O)-, -(C=S)-, -CH=CH-, -CsC-, -N(alquilo (C1-6))-, -N(fenilo)-, N-(alquilo (C1-6)fenilo)-, -N(CO-(CH2)1-10-COOH)- o -NH-; y sus sales aceptables farmacéuticamente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10227506A DE10227506A1 (de) | 2002-06-19 | 2002-06-19 | Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039689A1 true AR039689A1 (es) | 2005-03-09 |
Family
ID=29719281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030102142A AR039689A1 (es) | 2002-06-19 | 2003-06-17 | Difenilazetidinonas sustituidas, medicamentos que comprenden estos compuestos y su uso |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1517892B1 (es) |
| JP (1) | JP2005533072A (es) |
| CN (1) | CN1662493A (es) |
| AR (1) | AR039689A1 (es) |
| AT (1) | ATE478842T1 (es) |
| AU (1) | AU2003242616B2 (es) |
| BR (1) | BR0311940A (es) |
| CA (1) | CA2490109A1 (es) |
| DE (2) | DE10227506A1 (es) |
| EC (1) | ECSP045498A (es) |
| HN (1) | HN2003000183A (es) |
| HR (1) | HRP20041203A2 (es) |
| IL (1) | IL165791A0 (es) |
| MA (1) | MA27252A1 (es) |
| MX (1) | MXPA04012236A (es) |
| MY (1) | MY135850A (es) |
| NO (1) | NO20050073L (es) |
| NZ (1) | NZ537304A (es) |
| OA (1) | OA12868A (es) |
| PA (1) | PA8576001A1 (es) |
| PE (1) | PE20040577A1 (es) |
| PL (1) | PL372690A1 (es) |
| RS (1) | RS108504A (es) |
| RU (1) | RU2315754C2 (es) |
| SV (1) | SV2004001549A (es) |
| TN (1) | TNSN04255A1 (es) |
| TW (1) | TW200404774A (es) |
| UY (1) | UY27851A1 (es) |
| WO (1) | WO2004000804A1 (es) |
| ZA (1) | ZA200409381B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| US7447226B2 (en) * | 2003-10-31 | 2008-11-04 | International Business Machines Corporation | Methods and apparatus for continuous connectivity between mobile device and network using dynamic connection spreading |
| WO2005061452A1 (en) | 2003-12-23 | 2005-07-07 | Astrazeneca Ab | Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
| CN101115726A (zh) | 2004-12-03 | 2008-01-30 | 先灵公司 | 作为cb1拮抗剂的取代哌嗪 |
| WO2006107936A1 (en) * | 2005-04-04 | 2006-10-12 | Pontificia Universidad Catolica De Chile | The use of ezetimibe in the prevention and treatment of cholesterol gallstones |
| ATE450526T1 (de) | 2005-06-20 | 2009-12-15 | Schering Corp | Als antagonisten von histamin h3 geeignete piperidinderivate |
| SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| TW200811098A (en) | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
| BRPI0718052A2 (pt) * | 2006-11-02 | 2015-06-16 | Sanofi Aventis Deutschland | Difenilazotidinona substituída por ácido piperazino-1 sulfônico e possuindo propriedades farmacológicas melhoradas |
| DE102007002260A1 (de) | 2007-01-16 | 2008-07-31 | Sanofi-Aventis | Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| WO2010100255A1 (en) | 2009-03-06 | 2010-09-10 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
| CN101993403B (zh) | 2009-08-11 | 2012-07-11 | 浙江海正药业股份有限公司 | 氮杂环丁酮类化合物及医药应用 |
| ES2443016T3 (es) | 2009-08-26 | 2014-02-17 | Sanofi | Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5656624A (en) * | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
| CZ293957B6 (cs) * | 1995-10-31 | 2004-08-18 | Scheringácorporation | @@Azetidinony substituované cukernými zbytkyŹ použitelné jako hypocholesterolemikaŹ farmaceutický prostředek a kit je obsahující |
| DE10042447A1 (de) * | 2000-08-29 | 2002-03-28 | Aventis Pharma Gmbh | Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports |
-
2002
- 2002-06-19 DE DE10227506A patent/DE10227506A1/de not_active Withdrawn
-
2003
- 2003-01-17 HN HN2003000183A patent/HN2003000183A/es unknown
- 2003-06-02 SV SV2003001549A patent/SV2004001549A/es not_active Application Discontinuation
- 2003-06-04 JP JP2004514660A patent/JP2005533072A/ja not_active Abandoned
- 2003-06-04 CN CN03814087XA patent/CN1662493A/zh active Pending
- 2003-06-04 HR HR20041203A patent/HRP20041203A2/xx not_active Application Discontinuation
- 2003-06-04 NZ NZ537304A patent/NZ537304A/en unknown
- 2003-06-04 EP EP03760591A patent/EP1517892B1/de not_active Expired - Lifetime
- 2003-06-04 RU RU2005101091/04A patent/RU2315754C2/ru not_active IP Right Cessation
- 2003-06-04 CA CA002490109A patent/CA2490109A1/en not_active Abandoned
- 2003-06-04 WO PCT/EP2003/005815 patent/WO2004000804A1/de not_active Ceased
- 2003-06-04 DE DE50313017T patent/DE50313017D1/de not_active Expired - Lifetime
- 2003-06-04 OA OA1200400330A patent/OA12868A/en unknown
- 2003-06-04 AU AU2003242616A patent/AU2003242616B2/en not_active Ceased
- 2003-06-04 AT AT03760591T patent/ATE478842T1/de active
- 2003-06-04 BR BR0311940-8A patent/BR0311940A/pt not_active IP Right Cessation
- 2003-06-04 PL PL03372690A patent/PL372690A1/xx not_active Application Discontinuation
- 2003-06-04 RS YUP-1085/04A patent/RS108504A/sr unknown
- 2003-06-04 MX MXPA04012236A patent/MXPA04012236A/es active IP Right Grant
- 2003-06-16 UY UY27851A patent/UY27851A1/es unknown
- 2003-06-17 AR ARP030102142A patent/AR039689A1/es unknown
- 2003-06-17 TW TW092116319A patent/TW200404774A/zh unknown
- 2003-06-18 MY MYPI20032289A patent/MY135850A/en unknown
- 2003-06-18 PA PA20038576001A patent/PA8576001A1/es unknown
- 2003-06-18 PE PE2003000613A patent/PE20040577A1/es not_active Application Discontinuation
-
2004
- 2004-11-22 ZA ZA200409381A patent/ZA200409381B/xx unknown
- 2004-12-08 MA MA27990A patent/MA27252A1/fr unknown
- 2004-12-15 IL IL16579104A patent/IL165791A0/xx unknown
- 2004-12-16 EC EC2004005498A patent/ECSP045498A/es unknown
- 2004-12-17 TN TNP2004000255A patent/TNSN04255A1/en unknown
-
2005
- 2005-01-06 NO NO20050073A patent/NO20050073L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005533072A (ja) | 2005-11-04 |
| RS108504A (sr) | 2007-02-05 |
| EP1517892A1 (de) | 2005-03-30 |
| HRP20041203A2 (en) | 2005-06-30 |
| EP1517892B1 (de) | 2010-08-25 |
| OA12868A (en) | 2006-09-15 |
| RU2005101091A (ru) | 2005-07-10 |
| RU2315754C2 (ru) | 2008-01-27 |
| TW200404774A (en) | 2004-04-01 |
| HN2003000183A (es) | 2003-08-01 |
| IL165791A0 (en) | 2006-01-15 |
| DE10227506A1 (de) | 2004-01-08 |
| TNSN04255A1 (en) | 2007-03-12 |
| CA2490109A1 (en) | 2003-12-31 |
| AU2003242616A1 (en) | 2004-01-06 |
| DE50313017D1 (de) | 2010-10-07 |
| ECSP045498A (es) | 2005-03-10 |
| MA27252A1 (fr) | 2005-03-01 |
| CN1662493A (zh) | 2005-08-31 |
| BR0311940A (pt) | 2005-04-05 |
| NO20050073L (no) | 2005-01-06 |
| PA8576001A1 (es) | 2004-02-07 |
| MXPA04012236A (es) | 2005-02-25 |
| SV2004001549A (es) | 2004-03-19 |
| PE20040577A1 (es) | 2004-10-11 |
| ATE478842T1 (de) | 2010-09-15 |
| MY135850A (en) | 2008-07-31 |
| WO2004000804A1 (de) | 2003-12-31 |
| AU2003242616B2 (en) | 2008-12-11 |
| PL372690A1 (en) | 2005-07-25 |
| NZ537304A (en) | 2005-10-28 |
| UY27851A1 (es) | 2003-12-31 |
| ZA200409381B (en) | 2006-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039689A1 (es) | Difenilazetidinonas sustituidas, medicamentos que comprenden estos compuestos y su uso | |
| AR042437A1 (es) | Derivados de fluoroglicosidos heterociclicos, medicamentos que los contienen y usos | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| AR042438A1 (es) | Derivados de fluorglicosidos aromaticos, medicamentos que contienen estos compuestos y sus usos | |
| AR030230A1 (es) | Derivados de acilfenilurea, procedimiento para su preparacion y su empleo en la preparacion de medicamentos | |
| AR040477A1 (es) | Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos | |
| AR040474A1 (es) | Derivados de tiofenolglicosido, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos | |
| AR039690A1 (es) | Difenilazetidinonas sustituidas por grupos acidos, medicamentos que comprenden estos compuestos y su uso | |
| AR057712A1 (es) | Dihidropteridinonas en el tratamiento de enfermedades respiratorias | |
| AR036586A1 (es) | Nuevas dihidro-pteridinonas, procedimientos para su preparacion, su utilizacion como medicamentos y las formulaciones farmaceuticas que las contienen | |
| CO5630023A2 (es) | Fenil quinolinas y su uso como agentes estrogenicos | |
| AR063786A1 (es) | Derivados de 1,4 -benzotiepina-1,1 dioxido sustituidos con radicales bencilo, productos farmaceuticos que comprenden estos compuestos y su uso | |
| AR049393A1 (es) | Derivados fluoroglicosidicos de pirazoles con actividad inhibitoria de sglt 1; medicamentos que contienen estos compuestos y el empleo de los mismos en el tratamiento de la diabetes tipo i y tipo ii. | |
| AR025386A1 (es) | Moduladores de los receptores activados del proliferador de peroxisomas | |
| NO20034644D0 (no) | Fettsyrer med halvlange kjeder, glycerider og analoger som neutrofile overlevelses- og aktiveringsfaktorer | |
| AR047823A1 (es) | Derivados de 1,2,3,4-tetrahidroisoquinolina sustituida | |
| DK1996180T3 (da) | Benzamid- og pyridylamidderivater som antibakterielle midler | |
| AR017852A1 (es) | COMPUESTOS DE PIRAZOLO (3,4-b)PIRIDINA Y SUS SALES, UTILES COMO INHIBIDORES DE LAS PROTEINA-QUINASAS DEPENDIENTES DE CICLINA, Y LAS COMPOSICIONESFARMACEUTICAS QUE LOS CONTIENEN, EVENTUALMENTE ASOCIADOS CON UN AGENTE ANTICANCER. | |
| UY27357A1 (es) | Nuevos agentes antidiabéticos . | |
| AR079541A1 (es) | Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms | |
| ECSP045483A (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso | |
| CO5580768A2 (es) | Derivados de 4,5-diariltiazol como ligandos cb-1 | |
| AR041941A1 (es) | Derivado de 1-aminociclohexano sustituidos en la posicion 4 utilizado como receptor orl1 | |
| AR039403A1 (es) | Derivados de acil-4-carboxifenilurea y su uso como antidiabetico | |
| BRPI0312882B8 (pt) | derivados de pleuromutilina e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |